What are the potential benefits of Dihexa?

Reversal of cognitive deficits in Alzheimer's disease mouse models. New synapse formation (synaptogenesis) in hippocampus. Increased dendritic spine density. Oral bioavailability with effective blood-brain barrier penetration. Improved spatial learning and memory in aged animal models. Reduction of neuroinflammation (TNF-α, IL-1β reduction). Recovery of long-term potentiation (LTP) in damaged neural circuits

What compounds work synergistically with Dihexa?

Dihexa has been studied alongside Semax, Cerebrolysin, P21 for potential synergistic effects.

Dihexa — Mechanism, Benefits, Research & Synergies

Overview

Dihexa is a synthetic small peptide derived from angiotensin IV, developed at Washington State University as a hepatocyte growth factor (HGF) mimetic. It has demonstrated extraordinary potency as a cognitive enhancer in rodent models — reportedly 7 orders of magnitude more potent than BDNF in promoting synaptogenesis. It has the key advantage of oral bioavailability and blood-brain barrier penetration, addressing two major limitations of most neuropeptides. Animal studies show reversal of cognitive deficits from Alzheimer's-like conditions to near-normal levels.

Mechanism of Action

Dihexa binds to hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and acting synergistically with HGF to promote c-Met receptor signaling. The HGF/c-Met pathway drives: synaptogenesis (new synapse formation); dendritic spinogenesis; neuroplasticity via long-term potentiation (LTP) enhancement; and cell survival and migration. A 2014 study confirmed that HGF antagonist delivery blocked all procognitive effects of orally delivered dihexa, establishing HGF/c-Met as the essential pathway. Additionally activates PI3K/AKT signaling, reducing neuroinflammatory cytokines (TNF-α, IL-1β) and increasing anti-inflammatory IL-10.

Potential Benefits

Reversal of cognitive deficits in Alzheimer's disease mouse models
New synapse formation (synaptogenesis) in hippocampus
Increased dendritic spine density
Oral bioavailability with effective blood-brain barrier penetration
Improved spatial learning and memory in aged animal models
Reduction of neuroinflammation (TNF-α, IL-1β reduction)
Recovery of long-term potentiation (LTP) in damaged neural circuits

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range	10-20 mg/day (oral or topical); 1-5 mg/day subcutaneous
Beginner	10 mg/day oral or topical
Intermediate	15-20 mg/day oral
Advanced	20 mg/day oral; or 2-5 mg/day subcutaneous
Cycle Duration	4-8 weeks
Cycle Off	4-8 weeks

Dihexa is 10 million times more potent than BDNF in activating the HGF/MET signaling pathway for synaptogenesis. Very small doses are biologically active. Topical formulation (in DMSO) achieves CNS delivery. Oral bioavailability reasonable for a peptide due to small size and resistance to proteolysis.

Use our Reconstitution Calculator to determine exact syringe units for your protocol.

Routes of Administration

Oral Moderate

Oral administration achieves meaningful CNS levels due to lipophilicity and small size

Subcutaneous Injection High

Higher bioavailability; more consistent CNS delivery for research applications

Topical Moderate

Topical application in DMSO carrier achieves transdermal and CNS delivery; used in some research protocols

Read our full Routes of Administration Guide for detailed comparison of all delivery methods.

Stacking Protocols

Popular research stacks involving Dihexa:

Cognitive Enhancement Stack

Multi-pathway nootropic combining synaptogenesis, BDNF upregulation, and anxiolysis

Dihexa Semax Selank

Dihexa drives new synapse formation via HGF/MET; Semax raises BDNF directly; Selank provides anxiolytic and immune-modulating support.

Neurodegeneration Prevention Stack

Synaptogenesis combined with neuronal survival and mitochondrial support

Dihexa Humanin NAD+ Peptide Complex

Dihexa rebuilds synaptic connections; Humanin prevents neuronal apoptosis; NAD+ maintains neuronal energetics. Comprehensive neuroprotection stack.

Explore our complete Peptide Stacking Guide for more combinations and safety considerations.

Reconstitution

Typical Vial Size	5mg, 10mg
BAC Water	1-2ml per 5mg vial; DMSO-based topical also common
Storage	Refrigerate at 2-8°C after reconstitution
Shelf Life	28 days refrigerated; stable lyophilized at -20°C

Need exact syringe measurements?

Open Calculator Full Guide

Amino Acid Sequence

N-hexanoic acid-Tyr-Ile-6-aminohexanoic acid amide (modified dipeptide derivative)

Side Effects & Safety

Potential cancer risk via c-Met pathway (significant theoretical concern)
No long-term human safety data
Possible excessive neuroplasticity effects
HGF/c-Met is a known oncogenic pathway — cancer risk not established but theoretically concerning

Synergistic Compounds

The following compounds have been studied alongside Dihexa for potential complementary or synergistic effects:

Semax Cerebrolysin P21

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]
[object Object]
[object Object]

Quick Facts

Molecular Weight	476.7 g/mol
Research Status	Preclinical data only (rodent models). Potent but no human clinical trials published. Safety concerns exist including potential tumorigenicity via HGF/c-Met pathway (known oncogenic pathway). Significant research interest but caution warranted.

More Peptides in This Category

BPC-157 Selank Semax Cerebrolysin P21 Davunetide

Dihexa